Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $176.59 USD
Change Today +4.90 / 2.85%
Volume 7.3M
AMGN On Other Exchanges
Symbol
Exchange
AMGN is not on other exchanges.
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$177.50
Previous Close
$171.69
Day High
$181.81
Day Low
$176.00
52 Week High
07/31/15 - $181.81
52 Week Low
08/14/14 - $124.81
Market Cap
134.3B
Average Volume 10 Days
4.4M
EPS TTM
$8.25
Shares Outstanding
760.3M
EX-Date
08/13/15
P/E TM
21.4x
Dividend
$3.16
Dividend Yield
1.58%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.4M
Executive Vice President of Operations
Total Annual Compensation: $943.0K
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $899.9K
Compensation as of Fiscal Year 2014.

amgen inc (AMGN) Key Developments

Amgen Inc. Announces Appointment of Fred Hassan to Board of Directors

Amgen Inc. announced that on July 28, 2015, the Board of Directors of the Company appointed Fred Hassan as a director of the Company, effective immediately. Mr. Hassan is Partner and Managing Director at Warburg Pincus LLC since 2011. Mr. Hassan will serve as a member of the Audit Committee and the Compensation and Management Development Committee of the Board.

Amgen Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Amgen Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $5,370 million against $5,180 million a year ago. Operating income was $2,076 million against $3,278 million a year ago. Income before income taxes was $1,997 million against $1,758 million a year ago. Net income was $1,653 million or $2.15 per diluted share against $1,547 million or $2.01 per diluted share a year ago. Adjusted operating income was $2,551 million against $2,319 million a year ago. Adjusted income before income taxes was $2,472 million against $2,175 million a year ago. Adjusted net income was $1,977 million against $1,823 million a year ago. Capital Expenditures were $133 million against $173 million a year ago. Total revenues increased 4% versus the second quarter of 2014 to $5,370 million, with 6% product sales growth driven primarily by Enbrel (etanercept), Prolia (denosumab), Sensipar (cinacalcet), Kyprolis (carfilzomib) and XGEVA (denosumab). Unfavorable changes in foreign exchange rates impacted total revenue and product sales growth by approximately 2.5% points. The Company generated $2.7 billion of free cash flow in the second quarter of 2015 versus $2.1 billion in the second quarter of 2014. The increase was driven by improved working capital and higher operating income, as well as the termination of foreign exchange forward contracts For the six months, the company reported total revenues of $10,403 million against $9,701 million a year ago. Operating income was $4,098 million against $3,266 million a year ago. Income before income taxes was $3,873 million against $2,962 million a year ago. Net income was $3,276 million or $4.26 per diluted share against $2,620 million or $3.41 per diluted share a year ago. Adjusted operating income was $5,000 million against $4,719 million a year ago. Adjusted income before income taxes was $4,775 million against $3,875 million a year ago. Adjusted net income was $3,888 million against $3,261 million a year ago. For the year 2015, the company expects total revenues in the range of $21.1 billion to $21.4 billion and adjusted EPS in the range of $9.55 to $9.80. Previously, the company expected total revenues in the range of $20.9 billion to $21.3 billion and adjusted EPS in the range of $9.35 to $9.65. Adjusted tax rate to be in the range of 18% to 19%. This excludes the benefit of the federal R&D tax credit, which has not yet been extended for 2015. Capital expenditures to be approximately $700 million. GAAP tax rate guidance to be in the range of 14% to 16%. GAAP diluted EPS guidance in the range of $8.06 to $8.35.

Amgen Inc. Declares Dividend for the Third Quarter of 2015, Payable on September 8, 2015

Amgen Inc. announced that its Board of Directors declared a $0.79 per share dividend for the third quarter of 2015. The dividend will be paid on Sept. 8, 2015, to all stockholders of record as of the close of business on Aug. 17, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $176.59 USD +4.90

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.01 USD -0.15
Allergan plc $331.15 USD +2.28
Bristol-Myers Squibb Co $65.64 USD +1.18
Medtronic PLC $78.39 USD +0.11
Novo Nordisk A/S kr398.40 DKK +1.20
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 23.4x
Price/Sales 6.5x
Price/Book 4.9x
Price/Cash Flow 23.1x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.